Market OverviewThe global Allergic Rhinitis Drugs Market is valued at USD 1.90 Billion in 2024 and is projected to reach a ...
Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback